CSF2 and neoplasm: This OV has been engineered to have a double mutation in the γ34.5 and α47 genes (for cancer-selective replication and enhanced anti-tumor response, respectively), and the insertion of the GM-CSF human gene to enhance the anti-tumor immunity induction.